What is the Rational Combination Antihypertensive Therapy, and Whether Remains Such the Combination of ACE Inhibitor and Diuretic?

А.Д. Радченко

Abstract


This article is a review of the literature on the benefits of combination antihypertensive therapy as baseline one. There is explained the concept of rational combination. There has been discussed in detail the questions about whether the combination of angiotensin-converting enzyme (ACE) inhibitor and diuretic is rational and what diuretics and ACE inhibitors are better for long-term antihypertensive therapy.


Keywords


hypertension; combination therapy; angiotensin-converting enzyme inhibitors; diuretics

References


Беленков Ю.Н., Мареев В.Ю. От имени рабочей группы исследования ЭПИГРАФ. Эналаприл плюс индапамид в лечении стабильной артериальной гипертонии: оценка эффективности и безопасности рациональной комбинированной фармакотерапии (Эпиграф). Первые результаты Российского многоцентрового исследования // Сердце. — 2005. — Т. 2, № 4. — С. 3-10.

Беленков Ю.Н. и рабочая группа исследования

ЭПИГРАФ-2. Эналаприл плюс Индапамид в лечении АГ: оценка эффективности и безопасности рациональной фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2 // Сердце. — 2005. — Т. 4, № 5. — С. 277-286.

Горбась І.М. Програма профілактики і лікування артеріальної гіпертензії в Україні: підсумки виконання // Здоров’я України. Тематичний номер. — 2011. — № 3. — С. 32-34.

Корзун А.И., Кириллова М.В. Сравнительная характеристика ингибиторов АПФ. — Санкт-Петербург: ВМедА,

— 24 с.

Настанова та клінічний протокол надання медичної допомоги «Артеріальна гіпертензія». Наказ МОЗ України № 384 від 24.05.2012. — Київ, 2012. — 107 с.

Сіренко Ю.М., Радченко Г.Д., Поліщук С.А. від імені учасників багатоцентрового дослідження Еналаприл плюс індапамід при лікуванні артеріальної гіпертензії: оцінка ефективності та безпеки раціональної фармакотерапії застосування нефіксованої комбінації еналаприлу і індапаміду (ЕНЗИКС) (результати багатоцентрового дослідження ЕПІГРАФ-2 в Україні) // Укр. мед. часопис. — 2007. — № 3. — С. 61-70.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension //

J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials // Circulation. — 1998. — Vol. 97. —

Р. 2202-2210.

Amery A., Berthaux P., Bulpitt C. et al. Glucose intolerance during diuretic therapy: results of trial by the European Working Party on Hypertension in the Elderly // Lancet. — 1978. — Vol. 1. — P. 681-683.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. — 2002. — Vol. 288. — P. 2981-2997.

Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators // N. Engl. J. Med. — 1995. — Vol. 332. — P. 80-85

Ball S., Hall A., Murray G. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing // J. Am. Coll. Cardiol. — 1995. — Vol. 25. — S42-S46.

Banegas J., Esther Lopez-Garcia E., Dallongeville J. et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study //European Heart Journal. — 2011. — Vol. 32. — P. 2143-2152.

Barzilay J.I., Davis B.R., Cutler J.A. et al. Fasting glucose levels and incident di abetesmellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch Intern Med. — 2006. — Vol. 166. — P. 2191-2201.

Bjorklund K., Lind L., Zethelius B., Berglund L., Lithell H. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men // J. Hypertens. — 2004. — Vol. 22. — P. 1691-1697.

Byrd J.B., Zeng C., Tavel H.M. et al. Combination therapy as initial treatment for newly diagnosed hypertension // Am. Heart J. — 2011. — Vol. 162 (2). — P. 340-346.

Chockalingham A., Fodor J.G. Treatment of raised blood pressure in the population. The Canadian experience // Am. J. Hypertens. — 1998. — Vol. 11. — P. 747-749.

Cleland J.G., Tendera M., Adamus J. et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study // Eur. Heart J. — 2006. — Vol. 27 (19). — P. 2338-2345.

Colhoun H.M., Dong W., Poulter N.R. Blood pressure screening, management and control in England: results from the health survey for England 1994 // J. Hypertens. — 1998. — Vol. 16. — P. 747-752.

Corrao G., Nicotra F., Parodi A. et al. Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice // Hypertension. — 2011. — Vol. 58. — P. 566-572.

Dahloеf B., Devereux R.B., Kjeldsen S.E., Julius S.,

Beevers G., de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Daly C., Fox K., Remme W. еt al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy // Eur. Heart J. — 2005. — Vol. 26. — P. 1369-1378.

Dorsh M., Gillespie B., Erikson S. et al. Chlorthalidone reduces cardiovascular events compared with Hydrochlorthiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57. — P. 689-694.

Ernst M.E., Carter B.L., Goerdt C.J. et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure // Hypertension. — 2006. — Vol. 47. — Р. 352-358.

Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomised factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction //

Lancet. — 1995. — Vol. 345. — P. 669-685.

Fox K.M. EURopean trial оn reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362. — P. 782-788.

Guidelines on the management of stable angina pectoris. The Task Force on the management of stable angina pectoris of the European Society of Cardiology // Eur. Heart J. — 2013. — doi:10.1093/eurheartj/eht296

Girerd X. et al. / Analysis of the use of antihypertensive drugs in five European countries in 2010 / ESH London 29th April.

GISSI-3 Investigators (1994) GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico // Lancet. — 1994. — Vol. 343. — P. 1115-1122.

Goa K.L., Balfour J.A., Zuanetti G. (1996) Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction // Drugs. — 1996. — Vol. 52 (4). — P. 564-588.

Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patiens treated with indapamide SR 1,5mg versus enalapril 20 mg: the LIVE study // J. Hypertens. — 2000. — Vol. 18 (10). — P. 1465-1475.

Gottlieb S., Leor J., Shotan A. et al. Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients // Am. J. Cardiol. — 2003. — Vol. 92. — P. 1020-1025.

Gradman A.H., Parise H., Lefebvre P. et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study // Hypertension. — 2013. — Vol. 61 (2). — P. 309-318.

Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study // N. Engl. J. Med. — 2000. — Vol. 342. — P. 905-912.

Hirata K., Vlachopoulos C., Adji A., O’Rourke M.F. Benefits from angiotensin-converting enzyme inhibitor «beyond blood pressure lowering»: beyond blood pressure or beyond the brachial artery? [published correction appears in J. Hypertens. 2005; 23: 903-904] // J. Hypertens. — 2005. — Vol. 23. — P. 551-556.

http://www.theheart.org/article/1443111.do

Huang K., Dai G. The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat // J. Huazriong. Univ. Sci Technolog. Med. Sci. — 2002. — Vol. 22. — P. 17-20.

ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction // Lancet. — 1995. — Vol. 345. — P. 669-685.

Jamerson K., Weber M.A., Bakris G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2417-2428.

Jeunemaitre X., Charru A., Chatellier G. et al. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension // Am. J. Cardiol. — 1988. — Vol. 62. — P. 1072-1077.

Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) // Arch. Intern. Med. — 1997. — Vol. 157. — P. 2413-2465.

Keber L., Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study // Am. J. Cardiol. — 1995. — Vol. 76 (1). — P. 1-5.

Kikuya M., Hozava A., Ohokubo T. et al. Prognostic Significance of Blood Pressure and Heart Rate Variabilities // Hypertension. — 2000. — Vol. 36. — P. 901-906.

Kingma J.H., van Gilst W.H., Peels C.H. et al. (1994) Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS) // Eur. Heart J. — 1994. —

Vol. 15 (7). — P. 898-907.

Kober L., Torp-Pedersen C., Carlsen J.E. et al. For the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction //

N. Engl. J. Med. — 1995. — Vol. 33. — P. 1670-1676.

Krause T., Lovibond K., Caulfield M. et al. Management of hypertension: summary of NICE guildance // BMJ. — 2011. —

Vol. 343. — P. 4891.

Kronish I., Woodward M., Sergie Z. et al. Meta-Analysis Impact of Drug Class on Adherence to Antihypertensives Circulation. — 2011. — Vol. 123. — P. 1611-1621.

Langford H.G., Cutter G., Oberman A., Kansal P., Russell G. The effect of thiazide therapy on glucose, insulin and cholesterol metabolism and of glucose on potassium: results of a cross-sectional study in patients from the Hypertension Detection and Follow-up Program // J. Hum. Hypertens. — 1990. — Vol. 4. — P. 491-500.

Latini R., Maggioni A.P., Flather M. et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials // Circulation. — 1995. — Vol. 92 (10). — P. 3132-3137.

Leonetti G., Rappelli A., Salvetti A., Scapellato L. Long-term effects of indapamide: final results of a two-year Italianmulticenter study in systemic hypertension // Am. J. Cardiol. — 1990. — Vol. 65. — P. 67H-71H.

Madkour H., Gadallah M., Riveline B. et al. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension // Am. J. Cardiol. — 1996. — Vol. 77. — P. 23-25B.

Mancia G., Seravalle G., Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists // Am. J. Hypertens. — 2003. — Vol. 16. — P. 1066-1073.

Marre M., Garcia Puig J., Kokot F. et al. Effect of indapamide SR on microalbuminuria — the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) — rationale and protocol for the main trial // J. Hypertens Suppl. — 2003. — Vol. 21 (1). — P. 19-24S.

Marre M., Garcia-Puig J., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction hypertensive patients with type 2 diabetic: the NESTOR study // J. Hypertens. — 2004. — Vol. 22. — P. 1613-1622.

Messerli F., Bangalore S. Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction and Follies // Am. J. Med. — 2011. —

Vol. 124. — P. 896-899.

Mourad J.J., Waeber B., Zannad F. et al. Investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. — 2004. — № 22. — 2379-2386.

Multiple Risk Factor Intervention Trial Research Group. Mortality After 101/2 Years for Hypertensive Participants in the Multiple Risk Factor Intervention Trial // Circulation. — 1990. — Vol. 82. — P. 1616-1628.

Nissen S., Tuzcu E., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trail // JAMA. — 2004. — Vol. 292. — P. 2217-2225.

Pedrazzini G., Santoro E., Latini R. et al. GISSI-3 Investigators Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-3 trial // Am. Heart J. — 2008. — Vol. 155 (2). — P. 388-394.

Pilote L. Ramipril use in Canada: HOPE or HYPE? // JAMC. — 2003. — Vol. 168. — P. 568-569.

Pitt B., O’Neill B., Feldman R. et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function // Am. J. Cardiol. — 2001. — Vol. 87 (9). — P. 1058-63.

Plavinik F.L., Rodrigues C.I., Zanella M.T., Ribeiro A.B. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy // Hypertension. — 1992. — Vol. 19. — P. II26-II29.

Poulter N., Wedel H., Dahlof B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trail-Blood Pressure Lowering Arm // Lancet. — 2005. — Vol. 366. —P. 907-913.

PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or trancient ischaemic attack // Lancet. — 2001. — Vol. 358. — P. 1033-1041.

Rothwell P. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension // The Lancet. — 2010. — Vol. 375. — P. 938-948.

Shafi T., Appel L.J., Miller E.R. 3rd, Klag M.J., Parekh R.S. Changes in serum potassium mediate thiazide-induced diabetes // Hypertension. — 2008. — Vol. 52. — P. 1022-1029.

Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E. Efficacy of addon aldosterone receptor blocker in uncontrolled hypertension // Am. J. Hypertens. — 2006. — Vol. 19. — P. 750-755.

Siscovick D., Raghunathan T., Psaty B. et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest //

N. Engl. J. Med. — 1994. — Vol. 330. — P. 1852-1857.

Smithe S., Benjamin A., Bonow R. et al. AHA/ACCF Secondary Prevention and risk Reduction Therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guildeline from the American Heart Association and American College of Cardiology Foundation // Circulation. — 2011. — Vol. 124. — P. 00-00.

Solomon S.D., Rice M.M., A Jablonski K. et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial // Circulation. — 2006. — Vol. 114. — P. 26-31.

Stears A.J., Woods S.H., Watts M.M. et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension // Hypertens. — 2012. — Vol. 59. — P. 934-942.

Svensson P., de Faire U., Sleight P. Comparative effects of ramipril on ambulatory and office blood pressure: a HOPE substudy // Hypertension. — 2001. — Vol. 38. — P. 28-32.

Task Force Members. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // European Heart Journal. — 2008. — Vol. 29. — P. 2388-2442.

The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trail (ASCOT) Investigators, CAFE Steering Committee and Writing Committee. Differential Impact of Blood Pressure-Lowering Drugs on Cantral aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study // Circulation. — 2006. — Vol. 113. — P. 1213-1225.

The PEACE Trial Investigators. Angiotensin-converting–enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. — 2004. — 351. — 2058-2068.

The Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease // European Heart Journal. — 2004. — Vol. 25. — P. 1454-1470.

The Task force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guildelines on the management of stable angina pectoris // European Heart Journal. doi:10.1093/eurheartj/ehj001

Verdecchia P., Reboldi G., Angeli F. et al.Adverse prognostic significance of new diabetes in treated hypertensive subjects // Hypertension. — 2004. — Vol. 43. — P. 963-969.

Vermes E., Ducharme A., Bourassa M.G. et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the studies of left ventricular dysfunction (SOLVD) // Circulation. — 2003. — Vol. 107. — P. 1291-1296.

Wald D., Law M., Morris J. et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials // Am. J. Med. — 2009. — Vol. 122. — P. 290-300.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical values in the VALUE trial // Lancet. — 2004. — Vol. 363. — P. 2047-2049.

Wing L.M., Reid C.M., Ryan P. et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly // N. Engl. J. Med. — 2003. — Vol. 348. — P. 583-592.

Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis // Am. J. Cardiol. — 2002. — Vol. 89. — P. 18A-25A.

Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators // New Engl. J. Med. — 2000. — Vol. 342. — P. 145-153.

Zuanetti G., Latini R., Maggioni A.P. et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study // Circulation. — 1997. — Vol. 96. — P. 4239-4245.




DOI: https://doi.org/10.22141/2224-1485.1.33.2014.82677

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru